ME/CFS Prevalence Needs a Reset: Why Legacy Estimates No Longer Match the Real Burden

This paper presents corrected ME/CFS prevalence estimates using the US-CCUC™ framework, incorporating underdiagnosis, remission dynamics, and infection-associated expansion.

This paper is part of the CYNAERA ME/CFS Library, a growing resource, impacting how neuro-immune and infection associated chronic conditions are understood and counted.

By Cynthia Adinig

Executive Summary

ME/CFS is a multi-system neuroimmune condition with diverse onset pathways, but its true prevalence has been systematically underestimated for decades by diagnostic gaps, fragmented care, and structural undercounting. Pre-pandemic figures often cited by the CDC placed U.S. prevalence between 1 and 2.5 million individuals, while global estimates were frequently reported below 0.5 percent. These figures were shaped by narrow diagnostic criteria, low clinical recognition, fragmented care systems, and widespread underdiagnosis. Despite this complexity, ME/CFS has too often been counted through what healthcare systems can diagnose, not what patients are actually experiencing across communities. 

Recent data have clarified the scale of this underestimation. The CDC’s National Health Interview Survey (NHIS) found that 1.3 percent of U.S. adults reported having ME/CFS in 2021–2022, already exceeding many legacy assumptions (Vahratian et al., 2023). At the same time, large-scale longitudinal research has demonstrated that infection-associated onset represents a significant and measurable pathway into ME/CFS, making previously hidden population dynamics visible at scale.

The NIH RECOVER-Adult study, published in the Journal of General Internal Medicine, found that 4.5 percent of SARS-CoV-2 infected participants met 2015 Institute of Medicine clinical diagnostic criteria for ME/CFS at least six months after infection, compared with 0.6 percent of uninfected individuals (Vernon et al., 2025). The study also identified post-exertional malaise (PEM) as the most common symptom and found that 88.7 percent of participants with post-COVID ME/CFS also met criteria for Long COVID, reinforcing the overlap between these conditions while highlighting infection-associated expansion as one major contributor to overall prevalence.

CYNAERA’s US-CCUC™ framework interprets these findings within a broader recalibration of infection-associated chronic conditions (IACCs), without reducing ME/CFS to a single-cause illness. Updated modeling supports a Long COVID baseline of approximately 48.5 to 64.6 million U.S. adults, with a planning baseline of approximately 65 million adults. Because a substantial subset of ME/CFS cases emerges from this population, prevalence must be recalculated using population-level conversion dynamics in addition to legacy diagnostic counts.

Applying ME/CFS-concordant trajectory rates of 40% to 51% to the updated Long COVID population, and incorporating legacy baseline cases, produces a substantially expanded burden estimate. The ME/CFS classification burden is approximately 27.5 to 34.65 million U.S. adults. A conservative public-facing range, adjusted for overlap, diagnostic uncertainty, and structural invisibility, is approximately 18 to 26 million U.S. adults, with a planning midpoint of approximately 22 million.

These findings place ME/CFS within a broader IACC framework affecting tens of millions of Americans and establish it as one of the largest and least visible neuroimmune illnesses in the United States. Infection-associated pathways do not define ME/CFS, but they provide a large-scale lens through which the full burden of the condition becomes visible. This analysis builds directly on the abstract CRISPR Remission: A Flare-Aware Gene Editing Pathway Engine for Immune-Volatile Chronic Disease, presented at CRISPRMED26. That work centered Long COVID and ME/CFS as examples of immune-volatile, relapsing-remitting conditions where static models fail and where accurate population sizing is essential for therapeutic development.

This paper should be read alongside CYNAERA’s broader framework work, including Corrected National Prevalence Estimates for Infection-Associated Chronic Conditions (IACCs), The CYNAERA Remission Standard™, The Pathophysiology of Infection-Associated Chronic Conditions, and Environmental Triggers of ME/CFS, which together establish the structural basis for prevalence correction across multi-system chronic illness.

Why ME/CFS Prevalence Is Undercounted: Diagnostic Gaps, Underdiagnosis, and Post-Viral Expansion 

The argument for corrected prevalence is not speculative. It reflects long-standing convergence across federal reports, epidemiological research, clinical expertise, and patient-led organizations.

The National Academies of Sciences reported that 84% to 91% of individuals with ME/CFS remain undiagnosed, a finding echoed by CDC materials indicating that more than 9 in 10 individuals are not formally identified (Institute of Medicine, 2015; CDC, 2023). Advocacy organizations such as Solve M.E. and the Bateman Horne Center have consistently emphasized that diagnosed populations represent only a fraction of the true burden.

Epidemiological research further reinforces this gap. Studies led by Jason et al. demonstrate that prevalence varies significantly depending on case definition, with community-based sampling consistently identifying more cases than clinical registries (Jason et al., 2015). Nacul et al. similarly showed that prevalence estimates shift substantially based on diagnostic criteria, highlighting the instability of legacy figures (Nacul et al., 2011).

The post-COVID era has not introduced this undercount. It has exposed and amplified it at scale.

The RECOVER-Adult study provides one of the clearest signals of this shift. By applying standardized clinical diagnostic criteria in a large longitudinal cohort, it demonstrated that ME/CFS develops at a significantly higher rate following SARS-CoV-2 infection, with a hazard ratio of 4.93 compared to uninfected individuals (Vernon et al., 2025). It also confirmed that symptom expression is not static, noting that ME/CFS symptoms can wax and wane over time, a feature that complicates detection and contributes to undercounting.

At the same time, increasing recognition of overlap between ME/CFS, dysautonomia, mast cell activation-related conditions, and other neuroimmune disorders has further fragmented diagnostic capture. Patients are often distributed across multiple clinical categories rather than counted within a single condition, leading to systematic underrepresentation. CYNAERA’s Pathophysiology of Infection-Associated Chronic Conditions frames this as a systems-level issue, where multi-system disease expression is misinterpreted as separate conditions rather than a unified post-infectious process. Similarly, Environmental Triggers of ME/CFS demonstrates how symptom expression is influenced by external stressors, further complicating static diagnostic models.

Demographic invisibility also plays a role. CYNAERA’s Undercounted from Kabul to Kansas: The Hidden Men of IACC highlights how men with infection-associated chronic illness are frequently misclassified under cardiovascular risk, stress, or aging-related explanations, contributing to additional undercounting across populations. Taken together, these findings establish a consistent pattern: ME/CFS prevalence has historically been constrained by diagnostic visibility, not true population burden. The emergence of large scale chronic illness following SARS-CoV-2 infection has made this limitation impossible to ignore. What was once treated as uncertainty must now be understood as structural underestimation.

Correcting ME/CFS Prevalence: The US-CCUC™ Model for Infection-Associated Chronic Conditions

CYNAERA’s US-CCUC™ framework was developed to address a persistent structural problem in epidemiology: prevalence estimates for ME/CFS are shaped more by what healthcare systems are able to detect than by the actual number of people living with the disease. In conditions characterized by underdiagnosis, fluctuating symptom expression, and multi-system involvement, diagnostic capture functions as a limiting filter rather than a reliable measurement tool. As a result, traditional prevalence estimates reflect system visibility rather than population reality.

The US-CCUC™ model treats this gap as a correctable bias rather than an unavoidable limitation. Instead of relying on a single point estimate, it reconstructs prevalence by layering multiple known sources of undercounting, including hidden pre-pandemic cases, post-infectious expansion, demographic undercapture, misclassification across diagnostic categories, and remission-state exclusion. This approach mirrors standard epidemiological correction models used in infectious disease surveillance, where raw case counts are adjusted to account for under-testing and reporting gaps. By applying this logic to chronic post-infectious illness, the model shifts the focus from diagnosed cases to true population burden.

At its core, the framework integrates an updated Long COVID baseline with ME/CFS-concordant trajectory rates to estimate downstream disease burden. In simplified form, the model can be expressed as:

ME/CFS Classification Burden = Legacy ME/CFS Baseline + (Updated Long COVID Population × ME/CFS-Concordant Trajectory Rate)

Using a legacy baseline of approximately 1.5 million diagnosed cases, an updated Long COVID population of approximately 65 million adults, and a trajectory rate of 40% to 51%, the model produces a classification burden of approximately 27.5 to 34.65 million U.S. adults. This value represents the full population exhibiting ME/CFS-consistent illness patterns, regardless of diagnostic status.

True ME/CFS Prevalence in the U.S.: Corrected Estimates in the Long COVID Era

Under the 2026 US-CCUC™ revision, ME/CFS prevalence must be interpreted within the expanded Long COVID population and the broader IACC framework. The classification burden of approximately 27.5 to 34.65 million adults reflects the full modeled population with ME/CFS-consistent trajectories, including individuals who are undiagnosed, misclassified, or experiencing fluctuating symptoms. However, for public communication and near-term planning, CYNAERA distinguishes this from a more conservative reporting range that accounts for overlap, diagnostic uncertainty, and structural invisibility.

This conservative public-facing range is estimated at approximately 18 to 26 million U.S. adults, with a planning midpoint of approximately 22 million. The distinction between these ranges is not a contradiction, but a recognition of different use cases. The classification burden reflects total system impact, while the conservative range provides a more cautious estimate for policy and communication contexts where overstatement carries risk.

The key shift is not the exact number, but the scale. ME/CFS is no longer a rare or marginal condition confined to a small patient population. It is a large-scale post-viral neuroimmune illness affecting tens of millions of Americans and contributing significantly to the overall burden of infection-associated chronic conditions. Within the broader US-CCUC™ framework, this places ME/CFS as a major component of an IACC population estimated to affect approximately 75 to 90 million Americans, with a substantial proportion experiencing overlapping syndromes.

Remission vs. Recovery in ME/CFS: Why Symptom Improvement Does Not Mean Cure

A critical limitation in prevalence modeling for ME/CFS and Long COVID is the interpretation of symptom change over time. Most datasets rely on cross-sectional or point-in-time reporting, where individuals are classified based on whether they currently experience symptoms. This approach is poorly suited for illnesses defined by fluctuating function, delayed symptom worsening, and relapse after ordinary exertion. ME/CFS diagnostic guidance recognizes post-exertional malaise, unrefreshing sleep, cognitive impairment, and orthostatic intolerance as core features, which means disease activity cannot be accurately captured by a single symptom snapshot (Institute of Medicine, 2015; CDC, 2024).

The NIH RECOVER-Adult study strengthens this point because it identified post-COVID ME/CFS using 2015 Institute of Medicine clinical diagnostic criteria and found that 4.5% of infected participants met criteria at least six months after SARS-CoV-2 infection, compared with 0.6% of uninfected participants. The same study reported that post-exertional malaise was the most common ME/CFS symptom among infected participants and noted that symptoms may wax and wane, meaning some cases may be missed when assessment occurs during lower-symptom periods (Vernon et al., 2025). This directly supports CYNAERA’s position that prevalence estimates based on current symptom status risk excluding people who remain biologically vulnerable but temporarily more stable.

Longitudinal Long COVID evidence points in the same direction. A population-based nested case-control study found that 67.6% of individuals with post-COVID syndrome continued to experience persistent symptoms more than a year after infection, with fatigue, cognitive dysfunction, and exercise intolerance remaining dominant and PEM associated with more severe disease (Peter et al., 2025). Davis et al. (2021) similarly documented prolonged multisystem Long COVID symptoms, with fatigue, PEM, and cognitive dysfunction among the most frequent symptoms after month six. These studies do not describe a simple recovery curve. They describe a chronic, fluctuating disease pattern.

This is where CYNAERA’s Remission Standard™ becomes essential. In the absence of FDA-approved curative therapies for ME/CFS or Long COVID, symptom improvement should not automatically be interpreted as disease resolution. A patient may experience reduced symptoms because they are pacing, avoiding environmental triggers, limiting activity, receiving supportive care, or temporarily operating below the threshold that provokes relapse. Within the CYNAERA Remission Standard™, that state is better understood as improved stability, function, flare control, and resilience, not disappearance of disease vulnerability. In prevalence modeling, this distinction matters because misclassifying remission as cure removes patients from the denominator even when relapse risk remains.

Comorbidity and Persistent Vulnerability in ME/CFS: Dysautonomia, EDS, MCAS, and Long COVID Overlap

A further limitation in interpreting symptom resolution arises from the high degree of overlap between ME/CFS, Long COVID, and conditions characterized by chronic or lifelong physiological vulnerability. These include dysautonomia, postural orthostatic tachycardia syndrome (POTS), hypermobility spectrum disorders, Ehlers-Danlos syndromes, mast cell activation-related disorders, and other multi-system conditions frequently observed in post-infectious illness populations. These conditions are not typically understood through a simple cure framework. They are dynamic systems marked by variable expression, environmental sensitivity, autonomic instability, immune reactivity, and relapse vulnerability.

This overlap is increasingly visible in Long COVID research. Raj et al. (2021) described Long COVID-associated POTS, while Chadda et al. (2022) framed dysautonomia as a plausible contributor to Long COVID symptoms. Grach et al. (2024) found overlap between Long COVID, ME/CFS, generalized joint hypermobility, and orthostatic intolerance in a multisite clinic population. Ganesh et al. (2024) further discussed links among Long COVID, hypermobility spectrum disorders, ME/CFS, and mast-cell-related mechanisms. Taken together, these findings support the view that a meaningful subset of patients exists within overlapping terrain rather than within one clean diagnostic silo.

From a prevalence perspective, this matters because comorbidity overlap changes what “recovery” can reasonably mean. If a patient’s ME/CFS or Long COVID expression sits on top of dysautonomia, hypermobility, mast cell activation, or other persistent biological susceptibility, then a quiet symptom period cannot be assumed to represent elimination of the underlying disease process. It may represent stabilization, reduced trigger exposure, adaptive behavior, partial treatment response, or a temporary shift in disease state. When a condition overlaps with lifelong or genetically influenced disorders, absence of symptoms reflects stability, not disappearance of the underlying system vulnerability.

CYNAERA’s Pathophysiology of Infection-Associated Chronic Conditions and Environmental Triggers of ME/CFS apply this same terrain logic by treating symptoms as outputs of interacting immune, autonomic, vascular, neurological, connective tissue, and environmental systems. In this model, prevalence cannot be reduced to whether a patient is symptomatic on one survey date. A corrected denominator must account for people moving between active disease, partial stabilization, remission, relapse, and environmentally triggered worsening. Otherwise, the model will repeatedly undercount the people most likely to disappear from standard systems: those who reduce activity to survive, those who cannot access specialty care, and those whose symptoms are divided across multiple diagnostic labels.

Why Corrected ME/CFS Prevalence Changes Research, Policy, and Treatment Development

Corrected prevalence fundamentally changes the scale and framing of ME/CFS. Federal sources already acknowledge that the diagnosed population is only a fraction of the true burden, with the National Academies estimating that 84% to 91% of people with ME/CFS were undiagnosed and the CDC stating that more than 9 in 10 people with ME/CFS have not been diagnosed by a doctor (Institute of Medicine, 2015; CDC, 2024). The CDC’s NHIS estimate of 1.3% of U.S. adults with ME/CFS in 2021–2022 further shows that official prevalence has already moved beyond older assumptions (Vahratian et al., 2023). RECOVER then adds the post-COVID expansion signal by showing a substantially higher ME/CFS rate after SARS-CoV-2 infection than among uninfected participants (Vernon et al., 2025).

That convergence changes planning. If ME/CFS is modeled as affecting 1 to 2.5 million Americans,

it remains institutionally framed as neglected but relatively contained. If corrected modeling places the public-facing burden closer to 18 to 26 million, with a larger classification burden in the 27.5 to 34.65 million range under the 2026 US-CCUC™ revision, then ME/CFS becomes a major national driver of disability, workforce disruption, healthcare demand, and therapeutic unmet need. This scale affects NIH portfolio planning, clinical education, insurance modeling, employer accommodations, pediatric school supports, disability policy, and economic burden estimates.

Therapeutic development is especially sensitive to denominator accuracy. Underestimated prevalence distorts trial recruitment assumptions, endpoint design, investment rationale, and market sizing. CYNAERA’s CRISPR Remission: A Flare-Aware Gene Editing Pathway Engine for Immune-Volatile Chronic Disease, presented at CRISPRMED26, positioned Long COVID and ME/CFS as immune-volatile, relapsing-remitting conditions where timing, biological readiness, flare status, and remission state may influence whether advanced therapeutic approaches can be evaluated safely and effectively. In that context, prevalence correction is not separate from therapeutics. It is part of the infrastructure required to design and evaluate them.

CYNAERA’s internal framework papers should be cited as the connective tissue across this argument. Corrected National Prevalence Estimates for Infection-Associated Chronic Conditions (IACCs) supplies the denominator correction architecture. The CYNAERA Remission Standard™ supplies the distinction between remission and cure. The Pathophysiology of Infection-Associated Chronic Conditions explains why overlapping immune, autonomic, vascular, neurological, and environmental pathways require systems-level modeling. Undercounted from Kabul to Kansas: The Hidden Men of IACC extends the correction logic into demographic invisibility, especially where male patients are redirected into stress, aging, cardiovascular risk, or lifestyle explanations instead of post-infectious chronic illness.

Conclusion: ME/CFS Is a Large-Scale Multi-System Chronic Illness, Not a Rare Condition

ME/CFS prevalence has been systematically underestimated because the systems responsible for counting it were never built to capture its full burden. Diagnostic delays, inconsistent criteria, fragmented care pathways, limited specialist access, research exclusion, and misclassification across overlapping conditions have all kept millions of patients outside official estimates. Federal research, epidemiological data, patient experience, and community-led documentation now point toward a substantially larger affected population than legacy numbers suggest. CYNAERA’s US-CCUC™ framework provides a method for correcting this underestimation by integrating infection-associated expansion, diagnostic invisibility, remission dynamics, demographic under-capture, and comorbidity overlap into a unified model.

The result is not simply a revised number at approximately 18 to 26 million U.S. adults. It is a shift in how ME/CFS is understood. ME/CFS is not a marginal condition defined by who successfully receives a diagnosis. It is a large-scale, multi-system neuroimmune illness embedded within a broader landscape of infection-associated chronic conditions affecting tens of millions of Americans. Aligning prevalence with reality is the first step toward aligning research, care, policy, and therapeutic development with the true burden of disease.

Key Questions About ME/CFS Prevalence

Is ME/CFS a rare condition? 

No. While historically described as rare, corrected prevalence models suggest that ME/CFS affects tens of millions of Americans when underdiagnosis, remission states, and overlapping conditions are accounted for.

Why have ME/CFS prevalence estimates been so low? 

Most estimates rely on diagnosed cases, but over 80–90% of people with ME/CFS are never formally diagnosed. Fragmented care, inconsistent criteria, and misclassification across conditions all contribute to undercounting.

How does Long COVID affect ME/CFS prevalence? 

Long COVID has made infection-associated onset more visible at scale. Research shows a significant portion of Long COVID patients develop ME/CFS-like illness, expanding the observable population but not defining the condition as exclusively infection-triggered.

Does symptom improvement mean someone no longer has ME/CFS? 

No. ME/CFS is a relapsing, multi-system condition. Periods of symptom improvement are better understood as remission or stabilization, not cure. Many prevalence models exclude patients during these periods, leading to underestimation.

Why does corrected prevalence matter? 

Prevalence determines how diseases are prioritized. Underestimation affects research funding, clinical trials, healthcare access, and treatment development. Accurate population sizing is foundational to solving the condition.

How does CYNAERA calculate corrected prevalence? 

The US-CCUC™ framework integrates diagnosed cases, underdiagnosis rates, infection-associated expansion, remission dynamics, and comorbidity overlap to estimate true population burden rather than relying on clinical capture alone.

Why does ME/CFS still appear smaller in official data than it is in reality? 

Because current systems measure diagnosis, not disease. When conditions are difficult to diagnose, fluctuate over time, and overlap with other disorders, official counts reflect system limitations rather than true population burden.

CYNAERA Framework Papers and Core Research Libraries

This paper draws on a defined subset of CYNAERA Institute white papers that establish the methodological and analytical foundations of CYNAERA’s frameworks. These publications provide deeper context on prevalence reconstruction, remission, combination therapies and biomarker approaches. Our Long COVID Library,  ME/CFS Library, Lyme Library,  Autoimmune Library and CRISPR Remission Library are also in depth resources.

• Primary Chronic Trigger (PCT)™

• CYNAERA Remission Standard™

• The Science of Remission of IACC's

• Personalized CRISPR Remission™ for MECFS

• Personalized CRISPR Remission™ for Long COVID

• Why Drug Approval For ME/CFS Was Always A Setup

• Environmental Triggers of ME/CFS Flares

• Mankeeping Index™: Health Masking in Relationships

• ME/CFS Composite Diagnostic Fingerprint (MECFS - CDF)

• Corrected National Prevalence Estimates for (IACCs)

• Undercounted from Kabul to Kansas: The Hidden Men of IACC

• A Nobel-Scale Advance: AI-Powered CRISPR Platform for IACC's

  
  
  
  

Author’s Note:

All insights, frameworks, and recommendations in this written material reflect the author's independent analysis and synthesis. References to researchers, clinicians, and advocacy organizations acknowledge their contributions to the field but do not imply endorsement of the specific frameworks, conclusions, or policy models proposed herein. This information is not medical guidance.

Patent-Pending Systems

Bioadaptive Systems Therapeutics™ (BST) and affiliated CYNAERA frameworks are protected under U.S. Provisional Patent Application No. 63/909,951. CYNAERA is built as modular intelligence infrastructure designed for licensing, integration, and strategic deployment across health, research, public sector, and enterprise environments.

Licensing and Integration

CYNAERA supports licensing of individual modules, bundled systems, and broader architecture layers. Current applications include research modernization, trial stabilization, diagnostic innovation, environmental forecasting, and population level modeling for complex chronic conditions. Basic licensing is available through CYNAERA Market, with additional pathways for pilot programs, institutional partnerships, and enterprise integration.

About the Author 

Cynthia Adinig is the founder of CYNAERA, a modular intelligence infrastructure company that transforms fragmented real world data into predictive insight across healthcare, climate, and public sector risk environments. Her work sits at the intersection of AI infrastructure, federal policy, and complex health system modeling, with a focus on helping institutions detect hidden costs, anticipate service demand, and strengthen planning in high uncertainty environments.

Cynthia has contributed to federal health and data modernization efforts spanning HHS, NIH, CDC, FDA, AHRQ, and NASEM, and has worked with congressional offices including Senator Tim Kaine, Senator Ed Markey,  Representative Don Beyer, and Representative Jack Bergman on legislative initiatives related to chronic illness surveillance, healthcare access, and data infrastructure. In 2025, she was appointed to advise the U.S. Department of Health and Human Services and has testified before Congress on healthcare data gaps and system level risk.

She is a PCORI Merit Reviewer, currently advises Selin Lab at UMass Chan, and has co-authored research  with Harlan Krumholz, MD, Akiko Iwasaki, PhD, and David Putrino, PhD, including through Yale’s LISTEN Study. She also advised Amy Proal, PhD’s research group at Mount Sinai through its CoRE advisory board and has worked with Dr. Peter Rowe of Johns Hopkins on national education and outreach focused on post-viral and autonomic illness. Her CRISPR Remission™ abstract was presented at CRISPRMED26 and she has authored a Milken Institute essay on artificial intelligence and healthcare.

Cynthia has been covered by outlets including TIME, Bloomberg, Fortune, and USA Today for her policy, advocacy, and public health work. Her perspective on complex chronic conditions is also informed by lived experience, which sharpened her commitment to reforming how chronic illness is understood, studied, and treated. She also advocates for domestic violence prevention and patient safety, bringing a trauma informed lens to her research, systems design, and policy work. Based in Northern Virginia, she brings more than a decade of experience in strategy, narrative design, and systems thinking to the development of cross sector intelligence infrastructure designed to reduce uncertainty, improve resilience, and support institutional decision making at scale.

References

1. Bateman Horne Center (2023). ME/CFS: Diagnosis, prevalence, and clinical challenges. Salt Lake City: Bateman Horne Center.

2. Centers for Disease Control and Prevention (CDC) (2024). Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Available at: https://www.cdc.gov/me-cfs (Accessed: 2026).

3. Chadda, K.R., Blakey, E.E., Huang, C.L. and Jeevaratnam, K. (2022). Long COVID and postural orthostatic tachycardia syndrome: A review of autonomic dysfunction. Frontiers in Physiology, 13, 860198.

4. Davis, H.E., Assaf, G.S., McCorkell, L. et al. (2021). Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine, 38, 101019.

5. Ganesh, R., Grach, S.L., Marshall, B. et al. (2024). Clinical overlap between Long COVID, ME/CFS, and hypermobility spectrum disorders. Journal of Primary Care & Community Health, 15.

6. Grabowska, A.D., et al. (2023). The importance of estimating prevalence of ME/CFS in the population. Frontiers in Public Health, 11, 1275827.

7. Grach, S.L., Lafeber, M., Marshall, B. et al. (2024). Overlap of orthostatic intolerance, joint hypermobility, and ME/CFS in Long COVID populations. Frontiers in Medicine, 11.

8. Institute of Medicine (2015). Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an illness. Washington, DC: National Academies Press.

9. Jason, L.A., Sunnquist, M., Brown, A. et al. (2015). Examining case definition criteria for chronic fatigue syndrome and myalgic encephalomyelitis. Fatigue: Biomedicine, Health & Behavior, 3(2), pp. 57–68.

10. Jason, L.A., Mirin, A.A. (2021). Updating the national prevalence of ME/CFS in the United States and its relation to COVID-19. Fatigue: Biomedicine, Health & Behavior, 9(3), pp. 117–125.

11. Komaroff, A.L. (2021). Advances in understanding the pathophysiology of chronic fatigue syndrome. JAMA, 326(6), pp. 499–500.

12. Nacul, L.C., Lacerda, E.M., Pheby, D. et al. (2011). Prevalence of myalgic encephalomyelitis/chronic fatigue syndrome in three regions of England. BMC Medicine, 9, 91.

13. National Institutes of Health (NIH) RECOVER Initiative (2024). Post-COVID conditions and ME/CFS diagnostic overlap findings. Available at: https://recovercovid.org (Accessed: 2026).

14. Peter, R.S., Nieters, A., Kräusslich, H.G. et al. (2025). Persistence and severity of post-COVID syndrome symptoms in a population-based cohort. Nature Communications, 16.

15. Raj, S.R., Arnold, A.C., Barboi, A. et al. (2021). Long COVID and postural orthostatic tachycardia syndrome: A review of mechanisms and management. Clinical Autonomic Research, 31, pp. 365–368.

16. Solve M.E. Initiative (2024). ME/CFS: Prevalence, underdiagnosis, and disease burden. Available at: https://solvecfs.org (Accessed: 2026).

17. Vahratian, A., Blumberg, S.J., Terlizzi, E.P. and Schiller, J.S. (2023). Myalgic encephalomyelitis/chronic fatigue syndrome in adults: United States, 2021–2022. National Center for Health Statistics Data Brief, No. 488.

18. Vardaman, M. (2025). Time to correct the record on the global burden of ME/CFS. PubMed Central.

19. Vernon, S.D., Zheng, T., Do, H. et al. (2025). Incidence and prevalence of post-COVID-19 ME/CFS: A report from the RECOVER-Adult study. Journal of General Internal Medicine, 40, pp. 1085–1094.

20. Wood, M.S., et al. (2024). Impact of COVID-19 on ME/CFS-like illness prevalence in a large healthcare system. PLOS ONE.

How to Cite this Paper

Adinig, C. (2026). ME/CFS True Prevalence: Correcting Systemic Undercounting and Diagnostic Gaps. CYNAERA. Available at: https://www.cynaera.com/post/crispr-cas9-immunity